The prognostic markers for MCL as proposed by WHO for current clinical use incorporates: Age, performance status, CNS involvement at diagnosis, Stage (I, II vs III, IV), S. β2 microglobulin, S. LDH, morphology (Classic vs Blastoid). This evidence concerns the gene HLA-G and mantle cell lymphoma.